A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma

Inclusion Criteria:

1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosisincludes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDGcategory per WHO criteria. B. Gliomas that are preferred as ATDGs from pathological and clinical views, but notgiven for confirmed diagnosis.

2. Willingness to provide archival or newly obtained tumor tissues for current studyproposal.

3. Age equal or more than 20 years old (inform consent).

4. Life expectancy more than 3 months.

5. Patients fully understand the protocol with the willingness to have regularfollow-up.

6. Additional criteria for individual arms A. [Arm 1] Within 2 months after surgery forprimary tumor. B. [Arm 2] Total resection of primary tumors with tissue samplesavailable for test.

C. [Arm 3] (1) Total resection of primary tumors with the paired primary and recurrent tissue samples available for test. (2) IDH test suggesting wild-type.

Exclusion Criteria:

1. Gliomas diagnosed or preferred as other categories than ATDGs, such aspediatric-type diffuse gliomas, circumscribed astrocytic gliomas, and others.

2. Inability to cooperate by providing a complete medical history.

3. Patients disagree to provide archived tumor samples.

4. Undesirable compliance.

5. Having a known additional malignancy that is progressing or has required activetreatment within the past 3 years. Participants with basal cell carcinoma of theskin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervicalcarcinoma in situ) that have undergone potentially curative therapy are notexcluded.